Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations and Corporate Communications Douglas Ingram - President and Chief Executive Officer Dallan Murray - Executive Vice President and Chief Customer Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head of Research & Development Ian Estepan - Executive Vice President and Chief Financial Officer Confere ...

Sarepta Therapeutics (SRPT) reported $467.17 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 40.8%. EPS of $0.62 for the same period compares to -$0.46 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $399.88 million, representing a surprise of +16.83%. The company delivered an EPS surprise of +513.33%, with the consensus EPS estimate being -$0.15.While investors closely watch year-over-year changes in headline numbers -- revenue ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other ...

These two could become direct competitors relatively soon. Wave Life Sciences (WVE 6.39%) and Sarepta Therapeutics (SRPT 0.15%) are both riskier than the typical biotech, even when considering their stage of maturity. But with more uncertainty often comes more upside for risk-tolerant investors, and both companies are without a doubt on the very forefront of medicine, pushing the envelope beyond what was previously possible. Still, there's a clear winner here from an investment perspective, so let's analyze ...

I specialize in biotech and healthcare investment analysis, integrating clinical expertise with a solid foundation in business strategy. My approach leverages detailed risk-return charts and DCF analyses to clearly communicate the investment potential and associated risks. I advocate for a barbell portfolio strategy, with 90% allocated to secure assets such as Treasuries and broad-market ETFs, and 10% to high-alpha stocks. This balanced approach ensures that all recommendations are made within a context of ...

Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins. Investing in biotech companies, especially relatively small ones, can be a double-edged sword. Their shares often soar on strong clinical trial or regulatory news, but they can lose much of their value overnight if a study's results don't go their way. That makes many biotech stocks somewhat risky investments, but some could deliver excellent results for those who can stomach the risk. Two biotech co ...

It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT) . Shares have lost about 1.9% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Sarepta Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Q2 Earnings Beat, Sales Mis ...

After touching a nearly four-year high of $173.25 on June 21, shares of biotech firm Sarepta Therapeutics Inc (NASDAQ:SRPT) steadily worked lower on the charts, touching a more than two-month low of $123.50 on Aug. 9. It's not all bad, however, as SRPT posted gains in five its last six sessions, putting its year-to-date lead at 39.3%. What's more, a historically bullish signal is flashing on the charts. According to data from Schaeffer's Senior Quantitative Analyst Rocky White, Sarepta Therapeutics stock is ...

Sarepta Therapeutics (SRPT) staged quite a slide after its June 21 three-year high of $173.25, closing six of the last seven weeks lower. The shares are in positive territory so far this week, however, as the stock extends a bounce off the $125 level. Plus, a historically bullish signal could provide support on the charts, adding to the stock's 36% year-to-date lead. Sarepta Therapeutics stock's pullback has it within one standard deviation of its 126-day moving average. According to Schaeffer's Senior Quan ...

Both of these biotechs are highly innovative companies. We are still in a bull market, but the biotech industry, as measured by the SPDR S&P Biotech ETF (an industry benchmark), hasn't been keeping up with broader equities this year. That's no reason to avoid biotech stocks -- after all, some are doing just fine. That's the case with Vertex Pharmaceuticals (VRTX -0.41%) and Sarepta Therapeutics (SRPT 0.87%). Although these drugmakers continue to perform well, both look to have plenty of upside. Let's find o ...